Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
859.1M
Cash
26.67M
Avg Qtr Burn
-910.3K
Short % of Float
10.73%
Insider Ownership
85.01%
Institutional Own.
1.97%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Avatrombopag Details Thrombocytopenia , Chronic liver disease | Approved Quarterly sales | |
F351 (Hydronidone) Details Chronic hepatitis B, Liver fibrosis | Phase 3 Data readout | |
F573 Details Acute-on-Chronic liver failure | Phase 2 Data readout | |
F351 (Hydronidone) Details Non-alcoholic steatohepatitis , Liver fibrosis | Phase 2a Initiation | |
F230 Details Pulmonary arterial hypertension | Phase 1 Initiation |